This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records
Age ≥18 years at diagnosis. Diagnosed with ATTRv-CM or ATTRwt-CM, mixed phenotype. Treated with tafamidis, as VYNDAMAX 61 mg [one 61-mg tafamidis capsule] orally once daily for ≥12 months. Have had ≥1 pre- and ≥1 post-treatment neurologic assessments.
Exclusion Criteria:
History of any organ transplant. Individuals who are non-ambulatory. Prior or current treatment with any disease-modifying therapy (investigational or approved) alone or in combination, except tafamidis, as VYNDAQEL 80 mg [four 20-mg tafamidis meglumine capsules] orally once daily or VYNDAMAX 61 mg [one 61-mg tafamidis capsule] orally once daily. Peripheral neuropathy attributed to causes other than ATTR amyloidosis (eg, diabetes mellitus, B12 deficiency, hypothyroidism, shingles,Lyme disease, HIV infection, secondary to injury, chronic kidney disease). Patient's data fails to pass data quality checks.
